Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Palbociclib|DRUG: Aromatase Inhibitor
Sponsor: Dana-Farber Cancer Institute
Collaborators: Pfizer